Nuplazid suppresses esophageal squamous cell carcinoma growth in vitro and in vivo by targeting PAK4

BACKGROUND: Due to the high recurrence and low 5-year survival rates of esophageal squamous cell carcinoma (ESCC) after treatment, the discovery of novel drugs for recurrence chemoprevention is of particular importance. METHODS: We screened the FDA-approved drug library and found that Nuplazid, an a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Yaxing, Wu, Wenjie, Jiang, Yanan, Zhou, Hao, Yu, Yin, Zhao, Lili, Wu, Xiangyu, Lu, Xuebo, Yuan, Qiang, Wang, Zitong, Dong, Zigang, He, Luyun, Zhao, Jimin, Liu, Kangdong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980085/
https://www.ncbi.nlm.nih.gov/pubmed/34912075
http://dx.doi.org/10.1038/s41416-021-01651-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980085/
https://www.ncbi.nlm.nih.gov/pubmed/34912075
http://dx.doi.org/10.1038/s41416-021-01651-z

Ejemplares similares